Sight Sciences, Inc. (SGHT)
Largest Insider Buys in Sector
SGHT Stock Price History Chart
SGHT Stock Performance
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to …
Insider Activity of Sight Sciences, Inc.
Over the last 12 months, insiders at Sight Sciences, Inc. have bought $4.32M and sold $20.08M worth of Sight Sciences, Inc. stock.
On average, over the past 5 years, insiders at Sight Sciences, Inc. have bought $12.04M and sold $20.08M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Encrantz Staffan () — $4.42M. Raheja Manohar K. (EVP, Research & Development) — $7,400.
The last purchase of 551,802 shares for transaction amount of $2.06M was made by Encrantz Staffan () on 2024‑11‑21.
List of Insider Buy and Sell Transactions, Sight Sciences, Inc.
| 2024-11-21 | Sale | 551,802 1.07% | $3.73 | $2.06M | +6.65% | |||
| 2024-11-21 | 551,802 1.07% | $3.73 | $2.06M | +6.65% | ||||
| 2024-11-19 | EVP, Research & Development | 2,000 0.0039% | $3.70 | $7,400 | +0.40% | |||
| 2024-10-21 | Sale | Chief Commercial Officer | 21,831 0.0441% | $5.61 | $122,450 | -16.85% | ||
| 2024-10-18 | Sale | Chief Commercial Officer | 20,487 0.0408% | $5.98 | $122,451 | -22.53% | ||
| 2024-10-17 | Sale | Chief Commercial Officer | 20,970 0.0409% | $5.84 | $122,444 | -21.68% | ||
| 2024-10-16 | Sale | Chief Commercial Officer | 20,734 0.037% | $5.91 | $122,434 | -22.43% | ||
| 2024-10-02 | Sale | President and CEO | 12,727 0.023% | $5.99 | $76,184 | -14.56% | ||
| 2024-10-02 | Sale | Chief Technology Officer | 3,167 0.0057% | $5.99 | $18,958 | -14.56% | ||
| 2024-10-01 | Sale | Chief Financial Officer | 10,130 0.0186% | $6.08 | $61,590 | -12.71% | ||
| 2024-10-01 | Sale | Chief Operating Officer | 3,403 0.0063% | $6.08 | $20,690 | -12.71% | ||
| 2024-10-01 | Sale | Chief Legal Officer | 4,878 0.009% | $6.08 | $29,658 | -12.71% | ||
| 2024-07-02 | Sale | Chief Financial Officer | 10,497 0.0207% | $6.21 | $65,207 | 0.00% | ||
| 2024-07-02 | Sale | Chief Operating Officer | 3,525 0.007% | $6.21 | $21,897 | 0.00% | ||
| 2024-07-02 | Sale | Chief Legal Officer | 5,055 0.01% | $6.21 | $31,402 | 0.00% | ||
| 2024-07-01 | Sale | President and CEO | 12,569 0.0256% | $6.42 | $80,655 | 0.00% | ||
| 2024-07-01 | Sale | Chief Technology Officer | 3,128 0.0064% | $6.42 | $20,072 | 0.00% | ||
| 2024-05-17 | Sale | Chief Financial Officer | 13,066 0.0255% | $5.42 | $70,870 | +18.35% | ||
| 2024-04-03 | Sale | President and CEO | 12,571 0.0246% | $5.08 | $63,848 | +14.05% | ||
| 2024-04-03 | Sale | Chief Technology Officer | 3,128 0.0061% | $5.08 | $15,887 | +14.05% |
Insider Historical Profitability
| Encrantz Staffan | 4573920 9.0118% | $4.01 | 17 | 1 | <0.0001% | |
| D1 Capital Partners L.P. | 10 percent owner | 3000000 5.9108% | $4.01 | 1 | 1 | <0.0001% |
| Raheja Manohar K. | EVP, Research & Development | 98000 0.1931% | $4.01 | 1 | 0 | |
| Selnick Jesse | Chief Financial Officer | 249225 0.491% | $4.01 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Bank of America | $16.7M | 6.36 | 3.16M | -0.37% | -$61,939.68 | <0.01 | |
| UBS | $15.16M | 5.77 | 2.87M | -0.83% | -$127,744.32 | <0.01 | |
| Jackson Square LLC | $8.5M | 3.24 | 1.61M | -1.22% | -$104,670.72 | 0.37 | |
| The Vanguard Group | $8.22M | 3.13 | 1.56M | +5.54% | +$431,734.99 | <0.0001 | |
| BlackRock | $7.56M | 2.88 | 1.43M | -2.63% | -$204,737.26 | <0.0001 |